XOMA CORP (XOMA)

Company Profile

XOMA Corp. engages in the discovery and development of therapeutics derived from platform of antibody technologies. The company is headquartered in Emeryville, California and currently employs 12 full-time employees. The Company’s drug royalty aggregator business is focused on early to mid-stage clinical assets, primarily in Phase I and II. The firm has a portfolio of economic rights and royalty payments associated with partnered pre-commercial therapeutic candidates. Its royalty portfolio includes AFM13, AFM24, AB002 (proCase/E-WE thrombin), AB023 (xisomab, 3G3), AB054, AZD2936, AV-299 (ficlatuzumab), BAY1213790 (osocimab), CMP-001 (vidutolimod), Lysosomal Storage Disorders Enzymes, COM902, DAY101 (tovorafenib), vosaroxin, INCAGN1876, INCAGN1949, INCAGN02390, INCAGN2385, JNJ-63723283 (cetrelimab), MK-4830, MT-0169, CFZ533 (iscalimab), VPM087 (gevokizumab), NIS793, NIR178, G03-52-01, ebopiprant, PBF-680, PBF-677, PBF-999, PBF-1129, PBF-1650, RZ358, RZ402, faricimab (faricimab-svoa), TAK-079 (mezagitamab), Aldoxorubicin, and Arimoclomol. The firm's subsidiaries include XOMA Technology Ltd., XOMA (US) LLC, and XOMA UK Limited.

Company Info

XOMA CORP

Suite 310, 2200 Powell Street

Emeryville CALIFORNIA 94608

P: 15102047239

CEO: James Neal

Employees: 12

Website: https://www.xoma.com/